Dare Bioscience is a biopharmaceutical company. Co.'s product, XACIATO vaginal gel, is a single-dose prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. Co.'s portfolio includes three product candidates in clinical development: Ovaprene®, a hormone-free, monthly contraceptive; Sildenafil Cream, a proprietary cream formulation of sildenafil for topical administration to the vulva and vagina for treatment of female sexual arousal disorder; and DARE-HRT1, a combination bio-identical estradiol and progesterone intravaginal ring, for the treatment of menopausal symptoms, including vasomotor symptoms, as part of hormone therapy following menopause. The DARE stock yearly return is shown above.
The yearly return on the DARE stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2023 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the DARE annual return calculation with any dividends reinvested as applicable (on ex-dates).
|